ABOUT SEVITERONEL VT-464

Just like TNBC, the position of AR from the management of estrogen receptor-positive (ER+) breast cancer is an area of Energetic study. AR is expressed in up to 90% of ER+ tumors and preclinical data indicates that AR expression is linked to resistance to each tamoxifen and aromatase inhibitors in ER+ cell traces [fourteen–16]. Even though initia